Kenvue Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KVUE in the last 30 days.
See all $KVUE insider activity →Kimberly-Clark announced leadership changes ahead of its planned acquisition of Kenvue, expected to close in Q4 2026. Russ Torres, COO, will depart, while Jeff Melucci and Nelson Urdaneta will lead integration. Carlos De Jesus and Leonardo Curado will take on new roles in North America and EMEA, respectively. The acquisition remains subject to regulatory approvals.
Kenvue Inc.'s (KVUE) Chief Tech & Data Officer Michael Wondrasch acquired 66,028.99 common shares after 66,028.99 restricted stock units vested. 21,031 shares were withheld for taxes at $17.22 per share. The remaining 132,055.99 RSUs will vest in three equal installments through October 1, 2028, subject to continued service.
Kimberly-Clark (KMB) and Kenvue (KVUE) submitted market data to Brazil's competition authority, arguing their merger would cause a small increase in concentration, even if preventive diaper-rash creams are assessed separately from medicated products.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning KVUE (Kenvue Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent KVUE coverage spans financial news, mergers & acquisitions and corporate actions.
Kimberly-Clark announced leadership changes ahead of its planned acquisition of Kenvue, expected to close in Q4 2026. Russ Torres, COO, will depart, while Jeff Melucci and Nelson Urdaneta will lead integration. Carlos De Jesus and Leonardo Curado will take on new roles in North America and EMEA, respectively. The acquisition remains subject to regulatory approvals.
Small insider acquisition may signal confidence but size is modest.
Kimberly-Clark (KMB) and Kenvue (KVUE) submitted market data to Brazil's competition authority, arguing their merger would cause a small increase in concentration, even if preventive diaper-rash creams are assessed separately from medicated products.
Kimberly-Clark (KMB) launched a $7 billion debt exchange for Kenvue (KVUE) notes, tied to its planned acquisition. Holders can swap Kenvue notes for new Kimberly-Clark notes plus cash. The exchange, contingent on deal closure, seeks to remove restrictive covenants. EU regulatory review is ongoing, with a decision expected by October 13, 2026.
Clear integration leadership may support confidence in the deal.
AlphAI scores every news story that mentions KVUE with an AI model for sentiment and relevance, and aggregates insider trades from Kenvue Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kimberly-Clark announced leadership changes ahead of its planned acquisition of Kenvue, expected to close in Q4 2026. Russ Torres, COO, will depart, while Jeff Melucci and Nelson Urdaneta will lead integration. Carlos De Jesus and Leonardo Curado will take on new roles in North America and EMEA, respectively. The acquisition remains subject to regulatory approvals.
2 min readKenvue Inc.'s (KVUE) Chief Tech & Data Officer Michael Wondrasch acquired 66,028.99 common shares after 66,028.99 restricted stock units vested. 21,031 shares were withheld for taxes at $17.22 per share. The remaining 132,055.99 RSUs will vest in three equal installments through October 1, 2028, subject to continued service.
1 min readKimberly-Clark (KMB) and Kenvue (KVUE) submitted market data to Brazil's competition authority, arguing their merger would cause a small increase in concentration, even if preventive diaper-rash creams are assessed separately from medicated products.
1 min readKimberly-Clark (KMB) launched a $7 billion debt exchange for Kenvue (KVUE) notes, tied to its planned acquisition. Holders can swap Kenvue notes for new Kimberly-Clark notes plus cash. The exchange, contingent on deal closure, seeks to remove restrictive covenants. EU regulatory review is ongoing, with a decision expected by October 13, 2026.
2 min readKimberly-Clark (KMB) announced executive changes ahead of its planned acquisition of Kenvue (KVUE), expected to close in Q4 2026. Russ Torres, COO, will leave, while Jeff Melucci and Nelson Urdaneta will oversee integration. Segment leadership changes include Carlos De Jesus leading North America and Leonardo Curado leading EMEA. The deal is subject to regulatory approval.
2 min readKimberly-Clark (KMB) announced executive transitions. Russ Torres, President and COO, will depart for an external CEO role. Carlos De Jesus and Leonardo Curado will lead North America and EMEA, respectively, after the Kenvue (KVUE) acquisition, expected Q4 2026. The company expects the deal to close by year-end, subject to regulatory approvals.
2 min readKimberly-Clark launched a $7B debt exchange offer for Kenvue notes, ahead of its planned acquisition of Kenvue, expected to close in Q4 2026. The exchange involves new Kimberly-Clark notes and cash payments. The deal is conditional on regulatory approval, with the EU review extended to October 13, 2026.
2 min readA director of Kenvue Inc. (KVUE) acquired 1,300 deferred share units on September 28, 2026, according to an SEC Form 4 filing. The transaction was reported as part of the director's beneficial ownership.
1 min readKimberly-Clark (KMB) pays out nearly all its earnings as dividends, with a 5.16% yield. Its 2025 free cash flow ($1.64B) fell short of dividend payouts ($1.66B). The pending $48.7B Kenvue (KVUE) acquisition may prioritize integration costs over dividend growth, risking its multi-decade raise streak in 2027. Procter & Gamble (PG) has more room in its payout ratio.
2 min readKIMBERLY CLARK CORP (KMB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes DALLAS, September 28, 2026 – Kimberly-Clark Corporation (NASDAQ: KMB) (“ Kimberly-Clark ”) announced today the commencement, in connection with its previou
2 min read
